StockNews.AI
INDV
Benzinga
180 days

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

1. Fiscal guidance missed expectations. Stock plunged sharply. 2. Q4 sales beat estimates. EPS declined compared to last year. 3. Sublocade sales increased. Generic competition hurt Suboxone revenue. 4. Cost cuts announced. $50M reinvested in pipeline protection.

4m saved
Insight
Article

FAQ

Why Bearish?

The guidance miss and lower revenue forecast have spooked investors, similar to past earnings shortfalls that led to swift stock declines in healthcare stocks.

How important is it?

A 17% revenue decline forecast alongside competitive pressures and cost cuts signals significant near-term concerns likely influencing investor sentiment.

Why Short Term?

The immediate reaction with a 16.5% decline suggests a short-term impact; past cases show market volatility in response to conservative guidance.

Related Companies

ALKS

Related News